313 related articles for article (PubMed ID: 9824599)
21. High recurrence rate of Barrett's epithelium during long-term follow-up after argon plasma coagulation.
Mörk H; Al-Taie O; Berlin F; Kraus MR; Scheurlen M
Scand J Gastroenterol; 2007 Jan; 42(1):23-7. PubMed ID: 17190758
[TBL] [Abstract][Full Text] [Related]
22. Complete regression of Barrett's esophagus with heat probe thermocoagulation: mid-term results.
Michopoulos S; Tsibouris P; Bouzakis H; Sotiropoulou M; Kralios N
Gastrointest Endosc; 1999 Aug; 50(2):165-72. PubMed ID: 10425407
[TBL] [Abstract][Full Text] [Related]
23. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results.
Kochman ML
Gastrointest Endosc; 1999 Dec; 50(6):884-6. PubMed ID: 10644184
[No Abstract] [Full Text] [Related]
24. Prospective randomized trial of argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus in patients treated with antisecretory medication.
Bright T; Watson DI; Tam W; Game PA; Ackroyd R; Devitt PG; Schoeman MN
Dig Dis Sci; 2009 Dec; 54(12):2606-11. PubMed ID: 19101798
[TBL] [Abstract][Full Text] [Related]
25. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole.
Schulz H; Miehlke S; Antos D; Schentke KU; Vieth M; Stolte M; Bayerdörffer E
Gastrointest Endosc; 2000 Jun; 51(6):659-63. PubMed ID: 10840296
[TBL] [Abstract][Full Text] [Related]
26. [Argon plasma coagulation in Barrett's esophagus].
Nomura T; Yamashita K; Miyashita M; Tajiri T
Nihon Rinsho; 2005 Aug; 63(8):1458-62. PubMed ID: 16101240
[TBL] [Abstract][Full Text] [Related]
27. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor.
Fass R; Sampliner RE; Malagon IB; Hayden CW; Camargo L; Wendel CS; Garewal HS
Aliment Pharmacol Ther; 2000 May; 14(5):597-602. PubMed ID: 10792123
[TBL] [Abstract][Full Text] [Related]
28. [Endoscopic argon plasma coagulation of Barrett mucosa].
Brand B; Porthun M; von Schrenck T; Matsui U; Bohnacker S; Jäckle S; Thonke F; Seitz U; Soehendra N
Zentralbl Chir; 2000; 125(5):437-42. PubMed ID: 10929628
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
30. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Barrett's esophagus by endoscopic argon plasma coagulation.
Dumoulin FL; Terjung B; Neubrand M; Scheurlen C; Fischer HP; Sauerbruch T
Endoscopy; 1997 Oct; 29(8):751-3. PubMed ID: 9427496
[TBL] [Abstract][Full Text] [Related]
32. Ablation of residual Barrett's epithelium after endoscopic resection: a randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study).
Manner H; Rabenstein T; Pech O; Braun K; May A; Pohl J; Behrens A; Vieth M; Ell C
Endoscopy; 2014 Jan; 46(1):6-12. PubMed ID: 24353120
[TBL] [Abstract][Full Text] [Related]
33. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus.
Cooper BT; Neumann CS; Cox MA; Iqbal TH
Aliment Pharmacol Ther; 1998 Sep; 12(9):893-7. PubMed ID: 9768533
[TBL] [Abstract][Full Text] [Related]
34. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
[TBL] [Abstract][Full Text] [Related]
35. The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.
Watson JT; Moawad FJ; Veerappan GR; Bassett JT; Maydonovitch CL; Horwhat JD; Wong RK
Dig Dis Sci; 2013 Aug; 58(8):2253-60. PubMed ID: 23824407
[TBL] [Abstract][Full Text] [Related]
36. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
Basu KK; Bale R; West KP; de Caestecker JS
Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
[TBL] [Abstract][Full Text] [Related]
37. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation.
Kelty CJ; Ackroyd R; Brown NJ; Stephenson TJ; Stoddard CJ; Reed MW
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1289-96. PubMed ID: 15606390
[TBL] [Abstract][Full Text] [Related]
38. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients.
Overholt BF; Panjehpour M; Haydek JM
Gastrointest Endosc; 1999 Jan; 49(1):1-7. PubMed ID: 9869715
[TBL] [Abstract][Full Text] [Related]
39. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
Todd JA; Basu KK; de Caestecker JS
Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
[TBL] [Abstract][Full Text] [Related]
40. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
Jankowski JA; Anderson M
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
